1. nAMD: Why Anatomical Outcomes Matter

3. Program Overview

4. PIER Study: Anatomical Measures as Predictors of VA in Ranibizumab-Treated Eyes

5. Brolucizumab Achieved Superior Reductions in CST From Baseline to Week 16 and Week 48; This Difference Was Maintained at Week 96

6. HAWK and HARRIER: Study Design

7. Fewer Patients on Brolucizumab 6 mg Had Disease Activity at Week 16, as Assessed by a Masked Investigator

8. In Both HAWK and HARRIER, Fewer Patients on Brolucizumab Had IRF and/or SRF at Weeks 16, 48, and 96

9. In Both HAWK and HARRIER, Fewer Patients on Brolucizumab Had Sub-RPE Fluid at Weeks 16, 48, and 96

10. Percentage of Patients Never Fluid-Free (Presence of IRF and/or SRF at All Visits) up to Week 48 and Week 96 Were Fewer With Brolucizumab

11. Points to Consider

12. Patient Case Presentation

13. Patient Case (cont)

14. Patient Case (cont)

15. Patient Case (cont)

16. Patient Case (cont)

17. Patient Case (cont)

18. Patient Case (cont)

19. Patient Case (cont)

20. Patient Case (cont)

21. Points for Discussion

22. HAWK/HARRIER: Study Design Week 12 to 16 Assessment

23. HAWK/HARRIER: Mean CST Change Over Weeks 12 to 16

24. Patients Treated With Brolucizumab Showed Less CST Increase Over Week 12 to 16: ≥ 75 µm Threshold Stratification

25. Fewer Patients on Brolucizumab 6 mg Had Disease Activity at Week 16, as Assessed by a Masked Investigator

26. Significance of Subretinal Fluid

27. Patient Case Presentation

28. Patient Case (cont)

29. Patient Case Presentation: Persistent Intraretinal Fluid

30. Patient Case (cont)

31. Patient Case (cont)

32. Patient Case (cont)

33. Patient Case (cont)

34. Concluding Remarks

35. Abbreviations

36. Abbreviations (cont)